Last edition
News about "Formosa Pharmaceuticals "
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110 HER2 ADC Biosimilar
Formosa Pharmaceuticals files a clinical trial application for TSY-110, a HER2-targeting Antibody Drug Conjugate (ADC) biosimilar positioned as a potential alternative to Roche’s Kadcyla.
Formosa Pharmaceuticals | 01/09/2026 | By News Bureau
Formosa Pharmaceuticals Partners with Singapore Eye Research Institute for Corneal Disease Therapies
Formosa Pharmaceuticals partners with Singapore Eye Research Institute to develop next-generation ophthalmic formulations using APNT nanoparticle technology and advanced clinical research expertise for corneal diseases.
Formosa Pharmaceuticals | 02/05/2026 | By News Bureau | 212
Exclusive licensing deal grants Arrotex rights to market clobetasol propionate ophthalmic suspension for post-surgical ocular inflammation and pain, expanding Formosa’s footprint in Oceania.
Formosa Pharmaceuticals | 23/02/2026 | By News Bureau | 187
Formosa Pharma Signs Licensing Deal with DAVI for Clobetasol Propionate Ophthalmic Suspension
The DÁVI licensing agreement includes upfront, commercialization milestones, and sales milestones, with additional considerations throughout the term of the agreement.
Formosa Pharmaceuticals | 04/11/2024 | By Aishwarya | 747
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy